The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

about

Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.

P2860

Q38947467-DCF16E75-DF6A-4026-AEF0-3B3AFA91BE59 Q42364461-1919FFEF-F497-4A9F-BEFB-4AB8B98EA01B

P2860

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

Item

http://www.wikidata.org/entity/Q38669520

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The combination of fluticasone ...... trial evidence and experience.

@en

type

Item

label

The combination of fluticasone ...... trial evidence and experience.

@en

prefLabel

The combination of fluticasone ...... trial evidence and experience.

@en

P1476

The combination of fluticasone ...... trial evidence and experience.

@en

P2093

Amir A Zeki

http://www.w3.org/2001/XMLSchema#string

John R Richards

http://www.w3.org/2001/XMLSchema#string

Timothy E Albertson

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

Dosing frequency and medication adherence in chronic disease

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects.

The impact of medication regimen factors on adherence to chronic treatment: a review of literature.

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study.

Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study.

The use of beta-agonists and the risk of death and near death from asthma.

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.

P304

43-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753465815619136

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287111657

http://www.w3.org/2001/XMLSchema#string

P698

26668137

http://www.w3.org/2001/XMLSchema#string

P921

asthma

P932

5933662

http://www.w3.org/2001/XMLSchema#string

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

about

P2860

P2860

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932